Insulet Co. (NASDAQ:PODD) Receives $292.06 Average PT from Brokerages

Insulet Co. (NASDAQ:PODD) has been given an average recommendation of “Moderate Buy” by the seventeen ratings firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $292.06.

Several equities research analysts recently issued reports on PODD shares. StockNews.com lowered shares of Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Royal Bank of Canada started coverage on shares of Insulet in a research report on Thursday, March 6th. They set an “outperform” rating and a $340.00 price objective on the stock. Citigroup lifted their target price on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Piper Sandler increased their price target on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, Wells Fargo & Company boosted their price objective on Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday, February 21st.

Insulet Stock Down 4.5 %

PODD opened at $245.26 on Friday. Insulet has a 1-year low of $160.19 and a 1-year high of $289.46. The firm’s 50 day simple moving average is $269.86 and its two-hundred day simple moving average is $259.53. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $17.22 billion, a PE ratio of 42.36, a PEG ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, equities analysts forecast that Insulet will post 3.92 EPS for the current year.

Insider Buying and Selling at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. SBI Securities Co. Ltd. bought a new position in shares of Insulet in the fourth quarter worth about $36,000. Itau Unibanco Holding S.A. bought a new position in Insulet in the 4th quarter worth about $42,000. SRS Capital Advisors Inc. increased its position in shares of Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 56 shares during the period. TD Private Client Wealth LLC raised its stake in shares of Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 56 shares in the last quarter. Finally, Friedenthal Financial purchased a new stake in shares of Insulet in the fourth quarter valued at approximately $57,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.